Is Pfizer Stock Primed for a Rebound?

After an extended period of decline, Pfizer’s shares are attracting renewed attention from Wall Street. A powerful combination of regulatory approval and upgraded analyst sentiment is injecting optimism into the beleaguered stock, prompting investors to question whether a sustained recovery is finally underway.

Strategic Approval and Analyst Confidence Fuel Optimism

The positive momentum stems from a significant regulatory milestone. The U.S. Food and Drug Administration (FDA) has granted approval for Pfizer’s Padcev to be used in a combination therapy with Merck’s Keytruda for the treatment of bladder cancer. This strategic win for Pfizer’s oncology pipeline is critical, as it demonstrates the company’s capacity to drive growth independent of its pandemic-related vaccine business. The market is starting to reassess Pfizer’s potential beyond its Covid-19 products.

Simultaneously, this development has not gone unnoticed by financial experts. Guggenheim Securities reinforced its bullish stance by significantly raising its price target to $35 and reiterating a Buy recommendation. This move signals a strong conviction in the stock’s substantial upside potential.

Institutional Accumulation and Solid Fundamentals

The shifting sentiment is also evident in the actions of major investors. Recent disclosures reveal that firms like Coldstream Capital Management have been substantially increasing their holdings. This “smart money” is strategically accumulating shares at current levels, anticipating a potential trend reversal.

Should investors sell immediately? Or is it worth buying Pfizer?

This optimism finds a foundation in the company’s recent quarterly performance. Pfizer’s Q3 earnings per share comfortably surpassed analyst estimates, while revenue from its core business remained robust. These results indicate a corporate resilience that has exceeded the expectations of many skeptics.

A Company in Transition

Pfizer is actively executing an aggressive transformation strategy to move beyond its Covid-centric image. The recent acquisition of Metsera highlights its ambition to establish a foothold in the highly lucrative market for obesity and metabolic disease treatments. The objective is unambiguous: to replace declining Covid-related revenue with new, blockbuster drugs.

Despite these operational strides, the equity’s performance has yet to fully reflect this progress. Year-to-date, the stock remains down approximately 16 percent, currently trading at €21.80. However, a key technical indicator, the RSI reading of 21.6, points to a severely oversold condition, which technically increases the probability of a near-term rebound.

Earnings projections for 2025 suggest stability. If Pfizer can successfully monetize its recent regulatory approvals and make headway in the weight-loss medication sector, the current valuation may later be viewed as a favorable entry point.